RAS Mutation Clinical Risk Score to Predict Survival after Resection of Colorectal Liver Metastases

Annals of Surgery

Volumn 269, Issue 1, 2019, Pages 120-126

  Brudvik, Kristoffer W ^a,b   Jones, Robert P ^c   Giuliante, Felice ^d   Shindoh, Junichi ^a,e   Passot, Guillaume ^a   Chung, Michael H ^a   Song, Juhee ^a   Li, Liang ^a   Dagenborg, Vegar J ^f   Fretland, Åsmund A ^b   Røsok, Bård ^b   De Rose, Agostino M ^d   Ardito, Francesco ^d   Edwin, Bjørn ^b   Panettieri, Elena ^d   Larocca, Luigi M ^d   Yamashita, Suguru ^a   Conrad, Claudius ^a   Aloia, Thomas A ^a   Poston, Graeme J ^c   Bjørnbeth, Bjørn A ^b   Vauthey, Jean Nicolas ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF TOKYO   (Japan)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

clinical score; colorectal liver metastases; liver resection; RAS mutation

Indexed keywords

BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; RAS PROTEIN; DNA; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL RISK SCORE; COLORECTAL LIVER METASTASIS; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE FREE INTERVAL; FEMALE; GENE MUTATION; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREOPERATIVE CHEMOTHERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR VOLUME; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; DNA MUTATIONAL ANALYSIS; ECHOGRAPHY; EPIDEMIOLOGY; FOLLOW UP; GENETICS; LIVER RESECTION; LIVER TUMOR; METABOLISM; METASTASIS; MORTALITY; MULTICENTER STUDY; MUTATION; PATHOLOGY; POSTOPERATIVE PERIOD; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURVIVAL RATE; UNITED STATES; X-RAY COMPUTED TOMOGRAPHY;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROPENSITY SCORE; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY; UNITED STATES;

EID: 85017567704     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002319     Document Type: Article

References (36)

1. Jones RP, Jackson R, Dunne DF, et al. Systematic review and meta-analysis of follow-up after hepatectomy for colorectal liver metastases. Br J Surg. 2012;99:477-486.
2. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
3. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125-135.
4. Kattan MW, Gonen M, Jarnagin WR, et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247:282-287.
5. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg. 2007;246:183-191.
6. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg. 2013;258:619-626.
7. Stremitzer S, Stift J, Gruenberger B, et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg. 2012;99:1575-1582.
8. Karagkounis G, Torbenson MS, Daniel HD, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013;119:4137-4144.
9. Mise Y, Zimmitti G, Shindoh J, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22:834-842.
10. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
11. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408-1417.
12. Douillard J-Y, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med. 2013;369:1023-1034.
13. Aloia TA, Zorzi D, Abdalla EK, et al. Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection. Ann Surg. 2005;242:172-177.
14. Kishi Y, Abdalla EK, Chun YS, et al. Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg. 2009;250:540-548.
15. Zalinski S, Abdalla EK, Mahvash A, et al. A marking technique for intraoperative localization of small liver metastases before systemic chemotherapy. Ann Surg Oncol. 2009;16:1208-1211.
16. Heagerty PJ, Zeger SL. Multivariate continuation ratio models: connections and caveats. Biometrics. 2000;56:719-732.
17. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinomametastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-1262.
18. Malik HZ, Prasad KR, Halazun KJ, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007;246:806-814.
19. Minagawa M, Yamamoto J, Kosuge T, et al. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis: development and validation. Arch Surg. 2007;142:269-276.
20. Rosen CB, Nagorney DM, Taswell HF, et al. Perioperative blood transfusion and determinants of survival after liver resection for metastatic colorectal carcinoma. Ann Surg. 1992;216:493-504.
21. Schiergens TS, Rentsch M, Kasparek MS, et al. Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases. Dis Colon Rectum. 2015;58:74-82.
22. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol. 2008;34:55-60.
23. Katz SC, Pillarisetty V, Bamboat ZM, et al. T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol. 2009;16:2524-2530.
24. Wilson SM, Adson MA. Surgical treatment of hepatic metastases from colorectal cancers. Arch Surg. 1976;111:330-334.
25. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-946.
26. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg. 1999;189:291-299.
27. Seeberg LT, Waage A, Brunborg C, et al. Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. Ann Surg. 2015;261:164-171.
28. Brudvik KW, Kopetz SE, Li L, et al. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg. 2015;102:1175-1183.
29. Brudvik KW, Mise Y, Chung MH, et al. RAS mutation predicts positive resection margins and narrower resection margins in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol. 2016;23:2635-2643.
30. Blazer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344-5351.
31. Andreou A, Kopetz S, Maru DM, et al. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012;256:642-650.
32. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299-304.
33. Shindoh J, Chun YS, Loyer EM, et al. Non-size-based response criteria to preoperative chemotherapy in patients with colorectal liver metastases: the morphologic response criteria. Curr Colorectal Cancer Rep. 2013;9:198-202.
34. Sorbye H, Mauer M, Gruenberger T, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg. 2012;255:534-539.
35. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30:2956-2962.
36. Ayez N, van der Stok EP, Grunhagen DJ, et al. The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. Eur J Surg Oncol. 2015;41:859-867.